Full Coverage

FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral...

                   
yahoo.com
May 21, 2008
        
Story Timeline:  197 days

Anesiva, Inc. today announced that the U.S. Food and Drug Administration has accepted the company's electronic supplemental New Drug Application filing to expand the indication for Zingo to treat pain associated with peripheral IV insertions and blood draws in adults. [read full story]                    

Add Comment
Latest article on this story:

FDA Accepts Zingo Supplemental Drug For Pain Treatment

 emaxhealth.com May 23, 2008
First article on this story:

FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral...

 prnewswire.com May 21, 2008
Selected publications with coverage of this story:
redorbit.com prnewswire.com medicalnewstoday.com biospace.com yahoo.com earthtimes.org emaxhealth.com pharmiweb.co.uk finanznachrichten.de
RELATED
Found 5 documents:
                   

FDA Accepts Zingo Supplemental Drug For Pain Treatment

emaxhealth.com
May 23, 2008
        

FDA has accepted Anesiva's electronic supplemental New Drug Application (sNDA) filing to expand the indication for Zingo to treat pain associated with peripheral IV insertions and blood draws in adults. Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system is already...

                   

FDA Accepts Anesiva's sNDA for Pain Drug

redorbit.com
May 22, 2008
        

Posted on: Thursday, 22 May 2008, 09:01 CDT Anesiva has announced that the FDA has accepted the company's electronic supplemental new drug application filing to expand the indication for Zingo to treat pain associated with peripheral IV insertions and blood draws in adults. The sNDA submission is...

                   

FDA Accepts Anesiva, Inc.'s Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated...

biospace.com
May 21, 2008
        

SOUTH SAN FRANCISCO, Calif., May 21 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV - News) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's electronic supplemental New Drug Application (sNDA) filing to expand the indication for Zingo to treat pain...

Anesiva: FDA accepts filing to expand indication for Zingo system

finanznachrichten.de
May 21, 2008
        

NEW YORK (Thomson Financial) - Anesiva Inc. Wednesday said the Food and Drug Administration has accepted the company's supplemental new drug application (sNDA) to expand the indication for the Zingo system to treat pain associated with peripheral intravenous insertions and blood draws in adults....

                   

FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral...

earthtimes.org
May 21, 2008
        

SOUTH SAN FRANCISCO, Calif., May 21 CA-FDA-Accepts-Zingo SOUTH SAN FRANCISCO, Calif., May 21 -- Anesiva, Inc. (Nasdaq: ANSV) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's electronic supplemental New Drug Application (sNDA) filing to expand the...

Related categories

Health Care, Patients, Pain, Swelling, Anesiva